Business
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in China and Ukraine
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in China and Ukraine.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in China and Ukraine\n\nOncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in China and Ukraine\n\nBATON ROUGE, LA--(Marketwired - November 10, 2015) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received Notices of Allowance for patents on ProscaVax™, OncBioMune's cancer vaccine nearing completion of a Phase 1 trial for prostate cancer, from the State Intellectual Property Office (SIPO) of the People's Republic of China (PRC) and the State Enterprise \"Ukrainian Institute of Industrial Property\" (Ukrainian Patent Office). The patents, titled \"Composition and Method for Treating Cancer\" -- Appln, No. 201080005114.4 (PRC) and Appln. No. A 2013 09855 (Ukraine) - add to the intellectual property of ProscaVax™ and protect the vaccine through 2031. A previous patent for ProscaVax™ has been granted in the United States (U.S. Patent 8,647,627), and another related U.S. Patent application has recently received a Notice of Allowance (U.S. application 14/137,060).\"We are very pleased with the allowance of the patents to extend protection of ProscaVax™ as a novel cancer vaccine,\" commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"Cancer rates soaring in China present a true health emergency and the number of cancer patients in the Ukraine now exceeds one million. We hope that one day ProscaVax™ will be able to provide a viable solution in these regions with a great need for innovative new cancer therapies.\"About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.F...